Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 2/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | NPR3 | P17342 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1330022 | 1.00 | CA1 (0.40) | CA1CA2CA7TDP1POLB | |
| SCHEMBL14593924 | 0.91 | CA1 (0.38) | CA1CA2CA7TDP1POLB | |
| SCHEMBL13028281 | 0.83 | CA1 (0.34) | CA1CA2CA7TDP1POLB | |
| SCHEMBL13613729 | 0.83 | CA14 (0.42) | CA1CA2CA7TDP1POLB | |
| SCHEMBL7551324 | 0.81 | NOS1 (0.39) | CA1CA2CA7TDP1POLB | |
| SCHEMBL18068808 | 0.81 | MMP8 (0.36) | CA1CA2CA7CTSLCTSB | |
| SCHEMBL7555924 | 0.81 | NOS1 (0.39) | CA1CA2CA7TDP1POLB | |
| SCHEMBL28851150 | 0.81 | CTSL (0.36) | CA1CA2CA7CTSLCTSB | |
| SCHEMBL30507610 | 0.80 | CA1 (0.39) | CA1CA2CA7TDP1POLB | |
| SCHEMBL12139937 | 0.80 | CA1 (0.39) | CA1CA2CA7TDP1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9120754-B2 | Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof | DOGWOOD PHARMACEUTICALS, INC. (US) | 2015-09-01 | — | — | US | disclosed |
| US-20120129837-A1 | Derivatives of Fluorene, Anthracene, Xanthene, Dibenzosuberone and Acridine and Uses Thereof | ALLERGAN SALES, LLC | 2012-05-24 | — | — | US | disclosed |
| US-8129519-B2 | Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof | ALLERGAN SALES, LLC | 2012-03-06 | — | — | US | disclosed |
| US-20110282075-A1 | METHOD FOR PREPARING VITTATALACTONE | ALBERT-LUDWIGS-UNIVERSITAT FREIBURG (DE) | 2011-11-17 | — | — | US | disclosed |
| WO-2011118855-A1 | PATTERN FORMING METHOD AND RESIST COMPOSITION | FUJIFILM CORPORATION (JP) | 2011-09-29 | — | — | WO | disclosed |
| US-7960578-B2 | Method for the synthesis of peptides without solvent | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2011-06-14 | — | — | US | disclosed |
| US-7829568-B2 | Substituted 5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-2-ylamine compounds and their use for producing drugs | GRUENENTHAL GMBH (DE) | 2010-11-09 | — | — | US | disclosed |
| US-20100137354-A1 | DERIVATIVES OF FLUORENE, ANTHRACENE, XANTHENE, DIBENZOSUBERONE AND ACRIDINE AND USES THEREOF | ALLERGAN SALES, LLC | 2010-06-03 | — | — | US | disclosed |
| US-20100016631-A1 | METHOD FOR THE SYNTHESIS OF PEPTIDES WITHOUT SOLVENT | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE(CNRS) (FR) | 2010-01-21 | — | — | US | disclosed |
| US-20080300256-A1 | Substituted 5,6,7,8-Tetrahydroimidazo[1,2-a]pyridin-2-ylamine Compounds and Their Use for Producing Drugs | GRUENENTHAL GMBH (DE) | 2008-12-04 | — | — | US | disclosed |
| US-7449447-B2 | Peptidomimetic NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2008-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129837-A1 | Derivatives of Fluorene, Anthracene, Xanthene, Dibenzosuberone and Acridine and Uses Thereof | WNT1, CTNND1, CTNNB1 | CA1 3779/4885CA2 3806/4885CA7 2508/4885 |
| US-20110282075-A1 | METHOD FOR PREPARING VITTATALACTONE | FNTA, LCAT, AAAS | CA1 1147/4885CA2 3934/4885CA7 1743/4885 |
| US-20080300256-A1 | Substituted 5,6,7,8-Tetrahydroimidazo[1,2-a]pyridin-2-ylamine Compounds and Their Use for Producing Drugs | CYP3A7, CYP3A5, CYP2D6 | CA1 4636/4885CA2 3726/4885CA7 2348/4885 |
| US-20100137354-A1 | DERIVATIVES OF FLUORENE, ANTHRACENE, XANTHENE, DIBENZOSUBERONE AND ACRIDINE AND USES THEREOF | WNT1, CTNND1, CTNNB1 | CA1 3779/4885CA2 3806/4885CA7 2508/4885 |
| US-20100016631-A1 | METHOD FOR THE SYNTHESIS OF PEPTIDES WITHOUT SOLVENT | NRDC, NPPA, RTF1 | CA1 562/4885CA2 2256/4885CA7 1365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.